Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide.
M Del ReVincenza ConteducaS CrucittaG GurioliChiara CasadeiG RestanteG SchepisiC LolliFederico CucchiaraRomano DanesiU De GiorgiPublished in: Prostate cancer and prostatic diseases (2021)
The present study demonstrates that cfDNA and exosome-RNA are both a reliable source of AR variants and their combined detection in liquid biopsy predicts resistance to AR signaling inhibitors.